Hospital
Harrison Medical Center
Harrison Medical Center was paid $66.23M by Medicaid between Jan 2018 and Dec 2024, across 523 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 17% of everything it billed.
33Billing provider infoHARRISON MEDICAL CENTER
SILVERDALE, WA 98383
SILVERDALE, WA 98383
33aNPI1518912609assigned 05/24/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$66.23M
24GClaims2,231,858
24DCodes billed523
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#8 of 49
Median peer was paid$20.06M
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 347,254 | $11.00M | |
| 2019 | 354,477 | $10.95M | |
| 2020 | 295,172 | $8.81M | |
| 2021 | 332,328 | $9.68M | |
| 2022 | 321,135 | $9.20M | |
| 2023 | 325,704 | $9.18M | |
| 2024incomplete | 255,788 | $7.40M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 17% | 117,437 | 98,311 | $11.36M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 61,325 | 56,092 | $6.73M |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.6% | 18,143 | 13,848 | $5.02M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.3% | 54,209 | 47,936 | $4.87M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.6% | 32,108 | 28,570 | $3.06M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.9% | 28,165 | 25,631 | $1.95M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 19,445 | 18,333 | $1.90M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 11,487 | 10,950 | $1.85M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 14,776 | 10,728 | $1.57M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2.2% | 6,467 | 4,011 | $1.47M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 10,845 | 10,127 | $1.39M |
| J9271 | Injection, pembrolizumab, 1 mg | 2.1% | 494 | 360 | $1.37M |
511 more codes
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.9% | 8,990 | $1.24M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 4,463 | $764K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 10,121 | $738K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 5,642 | $696K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.0% | 14,319 | $687K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 25,600 | $685K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 20,474 | $589K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 13,116 | $579K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,713 | $568K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 6,491 | $546K |
| 80053 | Comprehensive metabolic panel | <1% | 106,790 | $531K |
| 96415 | <1% | 2,391 | $525K | |
| 76830 | Ultrasound, transvaginal | <1% | 5,630 | $477K |
| 12001 | <1% | 2,165 | $453K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,020 | $439K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,911 | $383K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,775 | $378K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 8,442 | $369K |
| 29125 | <1% | 2,015 | $343K | |
| 76642 | <1% | 4,242 | $285K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,484 | $275K |
| 76801 | <1% | 4,522 | $270K | |
| 93971 | <1% | 3,079 | $270K | |
| 10060 | <1% | 1,385 | $267K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,705 | $257K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,919 | $248K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,991 | $242K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,454 | $229K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,426 | $225K |
| 76770 | <1% | 2,475 | $224K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 31,474 | $221K |
| 95811 | <1% | 616 | $216K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 466 | $209K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 12,054 | $206K |
| 76536 | <1% | 2,566 | $205K | |
| 96367 | <1% | 3,670 | $205K | |
| 12002 | <1% | 1,021 | $193K | |
| 12011 | <1% | 677 | $167K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 2,448 | $155K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,431 | $155K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,122 | $152K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,376 | $152K |
| 36415 | Collection of venous blood by venipuncture | <1% | 73,662 | $150K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 118,350 | $142K |
| 97161 | <1% | 3,320 | $141K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 359 | $141K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,840 | $137K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,743 | $137K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 19,328 | $136K |
| 77412 | <1% | 408 | $127K | |
| G0378 | Hospital observation service, per hour | <1% | 5,203 | $125K |
| 84484 | <1% | 27,640 | $124K | |
| 29581 | <1% | 1,015 | $120K | |
| J2357 | Injection, omalizumab, 5 mg | <1% | 383 | $112K |
| 50590 | <1% | 90 | $109K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,726 | $109K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,365 | $106K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 929 | $106K |
| 97602 | <1% | 763 | $105K | |
| 76870 | <1% | 1,211 | $103K | |
| 97113 | <1% | 2,588 | $103K | |
| 71250 | <1% | 2,108 | $100K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,072 | $98K |
| 76882 | <1% | 1,330 | $97K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 637 | $96K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,283 | $94K |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | <1% | 83 | $93K |
| 72141 | <1% | 738 | $93K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 368 | $93K |
| 70496 | <1% | 702 | $93K | |
| 95806 | <1% | 207 | $92K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 473 | $89K |
| 74178 | <1% | 565 | $84K | |
| 47563 | <1% | 46 | $82K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 55 | $81K |
| 70486 | <1% | 1,422 | $77K | |
| 80061 | Lipid panel | <1% | 18,316 | $73K |
| 84439 | <1% | 9,128 | $71K | |
| 77386 | <1% | 141 | $70K | |
| 73562 | <1% | 2,228 | $70K | |
| 77066 | Tomosynthesis, mammo | <1% | 2,598 | $69K |
| 80050 | General health panel | <1% | 11,752 | $69K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15,197 | $65K |
| 72100 | <1% | 4,414 | $64K | |
| 96523 | <1% | 1,479 | $63K | |
| 93970 | <1% | 727 | $62K | |
| 90715 | <1% | 3,539 | $61K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,609 | $60K |
| 73630 | <1% | 5,924 | $60K | |
| 70491 | <1% | 637 | $59K | |
| 10061 | <1% | 287 | $59K | |
| J9299 | Injection, nivolumab, 1 mg | <1% | 52 | $57K |
| 73030 | <1% | 4,739 | $57K | |
| 71271 | <1% | 677 | $56K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 23,503 | $54K |
| 87040 | <1% | 7,233 | $52K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,173 | $52K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,011 | $51K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,888 | $50K |
| 76982 | <1% | 1,327 | $49K | |
| 97162 | <1% | 1,377 | $49K | |
| 73130 | <1% | 5,042 | $49K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,383 | $49K |
| 29130 | <1% | 296 | $44K | |
| 74018 | <1% | 3,150 | $43K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 23,564 | $42K |
| 73610 | <1% | 5,280 | $40K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 36,516 | $40K |
| 96368 | <1% | 2,014 | $40K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,482 | $38K |
| 77065 | Tomosynthesis, mammo | <1% | 1,410 | $38K |
| 83880 | <1% | 4,830 | $37K | |
| 83605 | <1% | 6,719 | $36K | |
| 72040 | <1% | 2,145 | $36K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 36,697 | $35K |
| 73110 | <1% | 3,773 | $35K | |
| 82728 | <1% | 7,413 | $34K | |
| 86140 | <1% | 8,135 | $33K | |
| 85379 | <1% | 6,379 | $33K | |
| 82607 | <1% | 4,379 | $32K | |
| 73502 | <1% | 2,908 | $32K | |
| 86803 | <1% | 7,689 | $31K | |
| 87070 | <1% | 16,010 | $30K | |
| 82570 | <1% | 5,889 | $29K | |
| 83970 | <1% | 1,466 | $29K | |
| 77080 | <1% | 528 | $28K | |
| 36430 | <1% | 470 | $28K | |
| 29515 | <1% | 129 | $27K | |
| 93458 | <1% | 26 | $26K | |
| 85027 | <1% | 9,584 | $26K | |
| 84702 | <1% | 5,335 | $26K | |
| 73221 | <1% | 201 | $25K | |
| 77336 | <1% | 448 | $25K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 147 | $25K |
| 93017 | <1% | 330 | $25K | |
| 76942 | <1% | 381 | $24K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 33,387 | $23K |
| 70498 | <1% | 737 | $21K | |
| 77002 | <1% | 209 | $21K | |
| 11045 | <1% | 346 | $20K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 12 | $20K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 6,842 | $20K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 263 | $19K |
| 73564 | <1% | 4,188 | $19K | |
| 84403 | <1% | 2,364 | $18K | |
| 86592 | <1% | 4,352 | $18K | |
| 97166 | <1% | 451 | $18K | |
| 83550 | <1% | 7,068 | $18K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 3,667 | $17K |
| 92523 | <1% | 162 | $17K | |
| 83540 | <1% | 7,329 | $16K | |
| 97605 | <1% | 134 | $16K | |
| 85652 | <1% | 7,763 | $16K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,496 | $16K |
| 84153 | <1% | 2,854 | $15K | |
| 97165 | <1% | 424 | $15K | |
| 86038 | <1% | 2,374 | $14K | |
| 82533 | <1% | 1,429 | $14K | |
| 73140 | <1% | 1,913 | $14K | |
| 83735 | <1% | 10,620 | $13K | |
| 82105 | <1% | 1,370 | $13K | |
| 82670 | <1% | 956 | $13K | |
| 84481 | <1% | 2,346 | $13K | |
| 92526 | <1% | 319 | $13K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,025 | $12K |
| 81001 | <1% | 25,923 | $12K | |
| 86003 | <1% | 1,708 | $12K | |
| 84402 | <1% | 1,424 | $12K | |
| 59025 | Fetal non-stress test | <1% | 73 | $12K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,669 | $12K |
| 87186 | <1% | 11,233 | $12K | |
| 87340 | <1% | 3,948 | $12K | |
| 64400 | <1% | 41 | $11K | |
| 29105 | <1% | 43 | $11K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 12 | $11K |
| 69209 | <1% | 255 | $11K | |
| 85610 | <1% | 16,913 | $11K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,485 | $10K |
| 86480 | <1% | 667 | $10K | |
| 82565 | <1% | 2,698 | $10K | |
| 73080 | <1% | 1,554 | $10K | |
| 83690 | <1% | 24,202 | $10K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 22,914 | $10K |
| 82785 | <1% | 995 | $10K | |
| 82043 | <1% | 4,057 | $10K | |
| 87081 | <1% | 1,839 | $10K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 31,576 | $9K |
| 83001 | <1% | 899 | $9K | |
| 80076 | <1% | 1,976 | $9K | |
| 86850 | <1% | 5,070 | $9K | |
| 82075 | <1% | 15,340 | $9K | |
| 73590 | <1% | 1,482 | $9K | |
| 95819 | <1% | 61 | $9K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 27 | $9K |
| 72072 | <1% | 653 | $9K | |
| 82784 | <1% | 1,930 | $9K | |
| 81015 | <1% | 4,036 | $8K | |
| 85014 | <1% | 3,112 | $8K | |
| 73090 | <1% | 1,335 | $8K | |
| 84480 | <1% | 1,560 | $8K | |
| 87077 | <1% | 4,809 | $8K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 23,627 | $8K |
| 86376 | <1% | 665 | $8K | |
| 71101 | <1% | 1,525 | $8K | |
| 82746 | <1% | 2,236 | $7K | |
| 88307 | <1% | 457 | $7K | |
| 87641 | <1% | 738 | $7K | |
| 84146 | <1% | 631 | $7K | |
| 86900 | <1% | 5,886 | $7K | |
| 72110 | <1% | 270 | $7K | |
| 97116 | <1% | 575 | $7K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 19 | $7K |
| 96416 | <1% | 73 | $7K | |
| 86704 | <1% | 1,729 | $7K | |
| 72158 | <1% | 83 | $7K | |
| 86300 | <1% | 1,192 | $7K | |
| 86706 | <1% | 1,957 | $6K | |
| 80143 | <1% | 1,331 | $6K | |
| 74183 | <1% | 31 | $6K | |
| 86431 | <1% | 1,639 | $6K | |
| 80069 | <1% | 1,284 | $6K | |
| 87510 | <1% | 702 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,024 | $6K |
| 29505 | <1% | 27 | $6K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 45 | $6K |
| 82962 | <1% | 20,740 | $6K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 33 | $6K |
| 77334 | <1% | 106 | $5K | |
| J1447 | Injection, tbo-filgrastim, 1 microgram | <1% | 42 | $5K |
| 86780 | <1% | 516 | $5K | |
| 82950 | <1% | 1,392 | $5K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 83 | $5K |
| 84703 | <1% | 3,547 | $5K | |
| 81025 | <1% | 19,623 | $5K | |
| 86762 | <1% | 1,644 | $5K | |
| 72050 | <1% | 222 | $5K | |
| 87205 | <1% | 6,338 | $5K | |
| 86923 | <1% | 624 | $5K | |
| 82550 | <1% | 1,989 | $5K | |
| 97597 | <1% | 122 | $5K | |
| 84100 | <1% | 4,058 | $4K | |
| 87147 | <1% | 3,626 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 13,031 | $4K |
| 87522 | Neg quan hep c or qual rna | <1% | 361 | $4K |
| 86901 | <1% | 6,127 | $4K | |
| 84156 | <1% | 2,020 | $4K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 436 | $4K |
| 86200 | <1% | 1,045 | $4K | |
| 86695 | <1% | 461 | $4K | |
| 36591 | <1% | 1,017 | $4K | |
| 84112 | <1% | 459 | $4K | |
| 76937 | <1% | 90 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,746 | $4K |
| 83655 | <1% | 289 | $4K | |
| 84550 | <1% | 2,075 | $4K | |
| 83002 | <1% | 468 | $4K | |
| 83516 | <1% | 664 | $4K | |
| 82731 | <1% | 238 | $3K | |
| 86235 | <1% | 461 | $3K | |
| 75574 | <1% | 27 | $3K | |
| 97035 | <1% | 476 | $3K | |
| 90686 | <1% | 415 | $3K | |
| 80179 | <1% | 1,216 | $3K | |
| 83520 | <1% | 575 | $3K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 40 | $3K |
| 87660 | <1% | 634 | $3K | |
| 81003 | <1% | 7,433 | $3K | |
| 87480 | <1% | 702 | $3K | |
| 86708 | <1% | 870 | $3K | |
| 77300 | <1% | 60 | $3K | |
| 85018 | <1% | 1,739 | $3K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 150 | $3K |
| 86800 | <1% | 339 | $3K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 45 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 12,534 | $3K |
| 72131 | <1% | 71 | $3K | |
| 96376 | <1% | 11,279 | $3K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 439 | $2K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 4,570 | $2K |
| 78306 | <1% | 12 | $2K | |
| 82378 | <1% | 2,482 | $2K | |
| 82248 | <1% | 613 | $2K | |
| 96417 | <1% | 2,971 | $2K | |
| 84450 | <1% | 802 | $2K | |
| 72156 | <1% | 14 | $2K | |
| 74022 | <1% | 643 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,557 | $2K |
| 87210 | <1% | 2,060 | $2K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 108 | $2K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,850 | $2K |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 1,228 | $2K |
| 87430 | <1% | 2,664 | $2K | |
| 82247 | <1% | 299 | $2K | |
| 83615 | <1% | 2,347 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,623 | $2K |
| 72070 | <1% | 81 | $2K | |
| 86696 | <1% | 507 | $2K | |
| 80074 | <1% | 238 | $2K | |
| 80305 | <1% | 211 | $2K | |
| 73700 | <1% | 26 | $2K | |
| 86160 | <1% | 435 | $2K | |
| 81002 | <1% | 10,703 | $2K | |
| 86304 | <1% | 424 | $2K | |
| 84165 | <1% | 837 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 106 | $1K |
| 84460 | <1% | 888 | $1K | |
| 36592 | <1% | 183 | $1K | |
| 99152 | <1% | 2,815 | $1K | |
| 85730 | <1% | 1,876 | $1K | |
| 82677 | <1% | 63 | $1K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 398 | $1K |
| 86364 | <1% | 276 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 258 | $1K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 73 | $1K |
| 93880 | <1% | 14 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,060 | $1K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 58 | $1K |
| 73060 | <1% | 97 | $1K | |
| 73660 | <1% | 83 | $1K | |
| 77001 | <1% | 16 | $1K | |
| 82553 | <1% | 186 | $1K | |
| 86225 | <1% | 298 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 411 | $1K |
| 87045 | <1% | 273 | $1K | |
| 85048 | <1% | 323 | $994.06 | |
| 72146 | <1% | 12 | $988.98 | |
| 87807 | <1% | 1,219 | $918.14 | |
| 74174 | <1% | 14 | $875.72 | |
| 86694 | <1% | 65 | $854.86 | |
| 84132 | <1% | 2,127 | $844.01 | |
| 86308 | <1% | 675 | $830.32 | |
| 82803 | <1% | 1,518 | $823.27 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 14,837 | $777.78 |
| 87427 | <1% | 242 | $761.94 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,117 | $715.28 |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 24 | $712.30 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 17,368 | $711.90 |
| 72157 | <1% | 26 | $709.28 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,264 | $708.86 |
| A9270 | Non-covered item or service | <1% | 46,383 | $693.35 |
| G0008 | Administration of influenza virus vaccine | <1% | 434 | $691.88 |
| 82024 | <1% | 27 | $678.13 | |
| 87899 | <1% | 380 | $670.27 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,428 | $659.90 |
| 72082 | <1% | 12 | $633.43 | |
| 88185 | <1% | 31 | $628.71 | |
| 84520 | <1% | 379 | $618.63 | |
| 86147 | <1% | 81 | $613.92 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,649 | $593.61 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 18,843 | $586.36 |
| 86593 | <1% | 478 | $582.29 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 18,193 | $580.96 |
| 83721 | <1% | 139 | $556.92 | |
| 93321 | <1% | 13 | $542.61 | |
| 85045 | <1% | 420 | $531.25 | |
| 83883 | <1% | 109 | $527.46 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,828 | $519.06 |
| 82330 | <1% | 1,219 | $504.97 | |
| 73560 | <1% | 29 | $489.04 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,881 | $479.45 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,992 | $457.90 |
| 84436 | <1% | 109 | $451.67 | |
| 51798 | <1% | 203 | $443.10 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,578 | $426.25 |
| 97163 | <1% | 12 | $423.75 | |
| C1769 | Guide wire | <1% | 3,828 | $418.97 |
| J1815 | Injection, insulin, per 5 units | <1% | 914 | $410.73 |
| 87481 | <1% | 37 | $405.20 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,407 | $368.93 |
| 82947 | <1% | 288 | $361.61 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,995 | $339.53 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 11,823 | $336.44 |
| 0240U | <1% | 1,312 | $330.36 | |
| 86787 | <1% | 66 | $306.39 | |
| 82365 | <1% | 28 | $304.35 | |
| 93798 | <1% | 65 | $302.46 | |
| 84630 | <1% | 67 | $286.32 | |
| 73552 | <1% | 60 | $276.98 | |
| 82310 | <1% | 82 | $274.54 | |
| 83521 | <1% | 320 | $257.89 | |
| J3490 | Unclassified drugs | <1% | 106 | $255.45 |
| 74220 | <1% | 12 | $248.39 | |
| 73522 | <1% | 12 | $244.92 | |
| 82525 | <1% | 42 | $242.82 | |
| 94729 | <1% | 13 | $240.19 | |
| 88304 | <1% | 1,604 | $229.56 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 17,575 | $214.72 |
| 36416 | <1% | 2,004 | $212.83 | |
| D1351 | Sealant - per tooth | <1% | 31 | $205.80 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 345 | $205.53 |
| 82140 | <1% | 102 | $196.07 | |
| 86336 | <1% | 51 | $188.66 | |
| 87493 | <1% | 89 | $186.90 | |
| 74019 | <1% | 28 | $184.97 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,308 | $173.73 |
| 82172 | <1% | 25 | $159.77 | |
| 80047 | <1% | 17 | $158.80 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,034 | $153.43 |
| 82150 | <1% | 40 | $144.91 | |
| 84145 | <1% | 53 | $144.65 | |
| 87075 | <1% | 211 | $137.88 | |
| 80178 | <1% | 12 | $136.71 | |
| 72170 | <1% | 24 | $128.77 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 8,347 | $127.58 |
| 86146 | <1% | 12 | $127.11 | |
| 84238 | <1% | 12 | $122.47 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 4,605 | $116.78 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,251 | $114.64 |
| 83525 | <1% | 13 | $100.64 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 396 | $95.86 |
| 86039 | <1% | 13 | $95.18 | |
| 82627 | <1% | 14 | $92.52 | |
| 83993 | <1% | 12 | $91.44 | |
| 88184 | <1% | 29 | $89.83 | |
| 86258 | <1% | 12 | $87.62 | |
| 51702 | <1% | 27 | $85.59 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 51 | $84.90 |
| 84270 | <1% | 13 | $80.77 | |
| 85613 | <1% | 12 | $79.64 | |
| 96411 | <1% | 68 | $76.81 | |
| 84154 | <1% | 14 | $72.30 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 638 | $63.36 |
| 84295 | <1% | 365 | $59.31 | |
| 88342 | <1% | 370 | $57.90 | |
| 86334 | <1% | 34 | $56.73 | |
| 84425 | <1% | 17 | $56.50 | |
| 84590 | <1% | 16 | $56.35 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,532 | $54.84 |
| 87088 | <1% | 69 | $49.83 | |
| C1781 | Mesh (implantable) | <1% | 103 | $48.81 |
| 84155 | <1% | 39 | $44.48 | |
| 81422 | <1% | 66 | $38.26 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 557 | $38.16 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 1,487 | $35.20 |
| 87177 | <1% | 13 | $35.10 | |
| 87209 | <1% | 13 | $31.76 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,159 | $30.30 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 149 | $29.22 |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 262 | $28.36 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,561 | $27.40 |
| 81050 | <1% | 12 | $27.18 | |
| 82977 | <1% | 12 | $24.40 | |
| 85347 | <1% | 482 | $22.97 | |
| 88341 | <1% | 181 | $22.15 | |
| 82009 | <1% | 121 | $20.13 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 9,444 | $18.70 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,792 | $16.37 |
| G0009 | Administration of pneumococcal vaccine | <1% | 12 | $15.53 |
| 88311 | <1% | 17 | $15.49 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 234 | $14.90 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 581 | $13.31 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 484 | $13.27 |
| 0352U | <1% | 189 | $13.03 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 415 | $12.45 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 370 | $12.09 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,246 | $11.90 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 102 | $10.25 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,650 | $9.30 |
| 82270 | <1% | 15 | $8.35 | |
| 82945 | <1% | 15 | $8.23 | |
| 81000 | <1% | 49 | $6.67 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,026 | $5.97 |
| 87428 | <1% | 108 | $5.60 | |
| 84157 | <1% | 16 | $4.12 | |
| 85041 | <1% | 14 | $3.26 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 651 | $2.09 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 493 | $1.61 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 523 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 118 | $0.00 |
| C1729 | Catheter, drainage | 0% | 233 | $0.00 |
| 16020 | 0% | 14 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 199 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 40 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 297 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 81 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 41 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 45 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 201 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 45 | $0.00 |
| 15853 | 0% | 14 | $0.00 | |
| D1120 | Dental cleaning, child | 0% | 34 | $0.00 |
| 81513 | 0% | 36 | $0.00 | |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 191 | $0.00 |
| 96402 | 0% | 13 | $0.00 | |
| J1598 | Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg | 0% | 16 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 12 | $0.00 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 27 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 29 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 16 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 354 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 393 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 869 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 237 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 16 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 16 | $0.00 |
| 0346T | 0% | 57 | $0.00 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 73 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 371 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 16 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 72 | $0.00 |
| D1208 | Topical application of fluoride, excluding varnish | 0% | 29 | $0.00 |
| C1755 | Catheter, intraspinal | 0% | 29 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 45 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 13 | $0.00 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 92 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 14 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 56 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 18 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 186 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 20 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 37 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHULTZ, DAVID (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Franciscan Medical Group | Bremerton, WA | $4.45M |
| Falcon Physical Therapy and Fitness | Peyton, CO | $2.06M |
| Overlake Medical Clinics, LLC | Bellevue, WA | $1.77M |
| Harrison Medical Center | Bremerton, WA | $359K |
| Harrison Medical Center | Forks, WA | $26K |
| Lucedale Chiropractic Clinic, P.A. | Lucedale, MS | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.